Related references
Note: Only part of the references are listed.Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
Marjolein Soethoudt et al.
NATURE COMMUNICATIONS (2017)
Binge Ethanol Consumption Increases Inflammatory Pain Responses and Mechanical and Cold Sensitivity: Tigecycline Treatment Efficacy Shows Sex Differences
Susan E. Bergeson et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2016)
Low-Dose Cannabinoid Type 2 Receptor Agonist Attenuates Tolerance to Repeated Morphine Administration via Regulating μ-Opioid Receptor Expression in Walker 256 Tumor-Bearing Rats
Mingyue Zhang et al.
ANESTHESIA AND ANALGESIA (2016)
Morphine-induced antinociception and reward in humanized mice expressing the mu opioid receptor A118G polymorphism
Angela N. Henderson-Redmond et al.
BRAIN RESEARCH BULLETIN (2016)
Opioid and cannabinoid synergy in a mouse neuropathic pain model
Nicholas P. Kazantzis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Gender-specific pain responses in the formalin test using a synthetic tetracycline compound
H. Blanton et al.
JOURNAL OF PAIN (2016)
Tolerance to the antinociceptive and hypothermic effects of morphine is mediated by multiple isoforms of c-Jun N-terminal kinase
Matthew B. Yuill et al.
NEUROREPORT (2016)
Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway
Amey Dhopeshwarkar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal
Liting Deng et al.
BIOLOGICAL PSYCHIATRY (2015)
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials
M. E. Lynch et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2015)
Estimates of Pain Prevalence and Severity in Adults: United States, 2012
Richard L. Nahin
JOURNAL OF PAIN (2015)
Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase
David J. Marcus et al.
MOLECULAR PAIN (2015)
Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat
Alexa A. Wakley et al.
DRUG AND ALCOHOL DEPENDENCE (2014)
Mutation of Putative GRK Phosphorylation Sites in the Cannabinoid Receptor 1 (CB1R) Confers Resistance to Cannabinoid Tolerance and Hypersensitivity to Cannabinoids in Mice
Daniel J. Morgan et al.
JOURNAL OF NEUROSCIENCE (2014)
Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery
Elizabeth J. Rahn et al.
MOLECULAR PAIN (2014)
Morphine and Clonidine Combination Therapy Improves Therapeutic Window in Mice: Synergy in Antinociceptive but Not in Sedative or Cardiovascular Effects
Laura S. Stone et al.
PLOS ONE (2014)
Modulating the endocannabinoid system in human health and disease successes and failures
Pal Pacher et al.
FEBS JOURNAL (2013)
Regulation of mu-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance
John T. Williams et al.
PHARMACOLOGICAL REVIEWS (2013)
Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System
Mohamed Naguib et al.
ANESTHESIA AND ANALGESIA (2012)
Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells
Stefania Merighi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
The inhibition of the nitric oxide-cGMP-PKG-JNK signaling pathway avoids the development of tolerance to the local antiallodynic effects produced by morphine during neuropathic pain
Arnau Hervera et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
The Economic Costs of Pain in the United States
Darrell J. Gaskin et al.
JOURNAL OF PAIN (2012)
SPINAL CANNABINOID CB2 RECEPTORS AS A TARGET FOR NEUROPATHIC PAIN: AN INVESTIGATION USING CHRONIC CONSTRICTION INJURY
P. W. Brownjohn et al.
NEUROSCIENCE (2012)
Functional Selectivity in CB2 Cannabinoid Receptor Signaling and Regulation: Implications for the Therapeutic Potential of CB2 Ligands
Brady K. Atwood et al.
MOLECULAR PHARMACOLOGY (2012)
Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats
Gin C. Hsieh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cannabinoid-Opioid Interaction in Chronic Pain
D. I. Abrams et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects
Steven G. Kinsey et al.
NEUROPHARMACOLOGY (2011)
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain
Tannia Gutierrez et al.
PAIN (2011)
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain
V. Curto-Reyes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
CB2: a cannabinoid receptor with an identity crisis
Brady K. Atwood et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Anandamide Enhances IL-10 Production in Activated Microglia by Targeting CB2 Receptors: Roles of ERK1/2, JNK, and NF-κB
Fernando Correa et al.
GLIA (2010)
The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations
Ronald J. Tallarida et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling
Erica J. Melief et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings
Roger B. Fillingim et al.
JOURNAL OF PAIN (2009)
Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation
Edgar Alfonso Romero-Sandoval et al.
MOLECULAR PAIN (2009)
The Toll of Opioid-Induced Glial Activation: Improving the Clinical Efficacy of Opioids by Targeting Glia
Linda R. Watkins et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Management of Opioid Medications in Patients With Chronic Pain and Risk of Substance Misuse
Seddon R. Savage
CURRENT PSYCHIATRY REPORTS (2009)
Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury
Alfonso Romero-Sandoval et al.
ANESTHESIOLOGY (2008)
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain
J. Guindon et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Cannabinoid CB2 receptors in human brain inflammation
C. Benito et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Suicidal Thoughts and Behavior Among Adults With Self-Reported Pain Conditions in the National Comorbidity Survey Replication
Jennifer Brennan Braden et al.
JOURNAL OF PAIN (2008)
Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision
Alfonso Romero-Sandoval et al.
ANESTHESIOLOGY (2007)
The neurobiology of addiction: a neuroadaptational view relevant for diagnosis
George F. Koob
ADDICTION (2006)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833
GT Whiteside et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation
Jared Ehrhart et al.
JOURNAL OF NEUROINFLAMMATION (2005)
Synergistic interactions between cannabinoid and opioid analgesics
DL Cichewicz
LIFE SCIENCES (2004)
Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles
Y Grabovsky et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Women experience more pain and require more morphine than men to achieve a similar degree of analgesia
MS Cepeda et al.
ANESTHESIA AND ANALGESIA (2003)
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data
G Tanda et al.
PSYCHOPHARMACOLOGY (2003)
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
BL Bennett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
CB2 cannabinoid receptor-mediated peripheral antinociception
TP Malan et al.
PAIN (2001)